Symbolbild · KI-generiert
Sarepta Therapeutics, Inc. (DE)
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Sarepta Therapeutics is a US biotechnology company specialising in the development of RNA-based therapies and gene therapies for Duchenne muscular dystrophy (DMD). The company has several approved exon-skipping therapies on the market as well as the gene therapy Elevidys. Sarepta is regarded as a leading company in DMD treatment.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (DE) | SRPT | NASDAQ | 1,57 Mrd. USD |
| Forte Biosciences, Inc. | FBRX | NASDAQ | 1,57 Mrd. USD |
| AnaptysBio, Inc. | ANAB | NASDAQ | 1,58 Mrd. USD |
| Septerna, Inc. | SEPN | NASDAQ | 1,55 Mrd. USD |
| Innoviva, Inc. | INVA | NASDAQ | 1,55 Mrd. USD |
| First Tracks Biotherapeutics, Inc. | TRAX | NASDAQ | 1,54 Mrd. USD |
| Zymeworks Inc. | ZYME | NASDAQ | 1,60 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.